MedTrace Logo

Feasibility and Acceptability Study of the "O'Dide" Application in People Suffering From an Addiction

NCT04659954 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-12-19

No results posted yet for this study

Summary

Substance Use Disorders (SUD) are associated with cognitive schemas that lead to care attrition and mistrust towards care. Considering this within SUD management, it is important to establish a confident relation between the patient and the care team to favorize acre observance. However, it demands an important availability of the healthcare team, allowing for frequent interactions at all times, including at night and during days off. With the present study, the investigator postulated that an application called Ô DIDE for Digital Interaction for Detoxification Engagement, that aims to help the caregivers maintaining a link with the patient in order to facilitate confidence in the relationship, could favorize care observance especially consumption report.

Conditions

  • Substance-Related Disorders
  • Personality Disorders

Interventions

OTHER

Application O'DIDE

The intervention is the use of an application that aimed to favorize contact between the patient and the care team between the consultations.

Sponsors & Collaborators

  • Institut de Recherche en Santé Publique, France

    collaborator OTHER

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Juliette Salles, MD · University Hospital, Toulouse

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-07
Primary Completion
2023-02-10
Completion
2023-02-10

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04659954 on ClinicalTrials.gov